The shares of Amedica Corporation (NASDAQ:AMDA) currently has mean rating of 1.00 while 1 analysts have recommended the shares as “BUY”, 0 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.
The company’s mean estimate for sales for the current quarter ending Jun 16 is 5.16M by 1 analysts. The means estimate of sales for the year ending Dec-16 is 20.21M by 1 analysts.
The mean price target for the shares of Amedica Corporation (AMDA) is at 5.00 while the highest price target suggested by the analysts is 5.00 and low price target is 5.00. The mean price target is calculated keeping in view the consensus of 1 brokerage firms.
The average estimate of EPS for the current fiscal quarter for Amedica Corporation (AMDA) stands at -0.25 while the EPS for the current year is fixed at -1.04 by 1 analysts.
The next one year’s EPS estimate is set at -0.81 by 1 analysts while a year ago the analysts suggested the company’s EPS at -1.04.
In its latest quarter ended on 31st March 2016, Amedica Corporation (AMDA) reported earnings of $-0.30. The posted earnings missed the analyst’s consensus by $-0.05 with the surprise factor of -20.00%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
On June 13, 2016 Amedica Corporation (AMDA) announced that it has submitted its responses to the Food and Drug Administration (FDA) in relation to the CASCADE clinical trial.
The CASCADE study compared the 24-month outcomes from single-level cervical fusion between Amedica’s porous silicon nitride versus bone autograft. Data showed that porous silicon nitride achieved clinical and radiographic outcomes that were comparable to bone autograft.
“Porous silicon nitride is a synthetic platform that can achieve spinal fusion without added bone graft, based on the results of our clinical trial,” said Dr. Sonny Bal, chairman and CEO of Amedica Corporation. “These outcomes are consistent with our understanding of the surface chemistry and nano-topography of silicon nitride. We believe the composite porous silicon nitride fusion device used in the CASCADE trial, if approved by the FDA, will improve patient health. We are confident that we have addressed the questions raised by the FDA.”